The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Novo's US rival Eli Lilly's drug tirzepatide is also approved for weight loss in the EU. Tirzepatide has shown to cut heart ...

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

After losing market share in recent years, Nike faces near-term challenges such as the sales momentum among competitors. The Federal Trade Commission sued the drug middlemen that health plans use to ...